{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:30Z","timestamp":1787755890320,"version":"build-2784847793"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.transci.2025.104304","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T07:25:34Z","timestamp":1766215534000},"page":"104304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"65","author":[{"given":"Youssef","family":"Elemary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stakiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Goubran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sanayei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Kodad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"MacKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabuj","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elemary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.transci.2025.104304_bib1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.transci.2025.104304_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"10.1016\/j.transci.2025.104304_bib3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"10.1016\/j.transci.2025.104304_bib4","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41409-020-0836-2","article-title":"Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I\/II study (MOZAIC)","volume":"55","author":"Morland","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2025.104304_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000531940","article-title":"Mobilization strategies in myeloma patients intended for autologous hematopoietic cell transplantation","volume":"50","author":"Jantunen","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"5","key":"10.1016\/j.transci.2025.104304_bib6","first-page":"1525","article-title":"A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and \u201con-demand\u201d plerixafor in multiple myeloma patients treated with novel agents","volume":"109","author":"Mina","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.transci.2025.104304_bib7","first-page":"590.e1","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide \u00b1 plerixafor versus G-CSF \u00b1 plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"10.1016\/j.transci.2025.104304_bib8","first-page":"1460","article-title":"Cost and clinical analysis of hematopoietic progenitor cell mobilization with plerixafor","volume":"51","author":"Shaughnessy","year":"2011","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.transci.2025.104304_bib9","article-title":"Innovations in hematopoietic stem-cell mobilization: from G-CSF and chemotherapy to CXCR4 ligands and niche modulation","volume":"36","author":"D\u2019Addio","year":"2023","journal-title":"Best Pract Res Clin Haematol"},{"issue":"28","key":"10.1016\/j.transci.2025.104304_bib10","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","article-title":"Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor versus placebo plus G-CSF for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.transci.2025.104304_bib11","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.bbmt.2009.08.005","article-title":"Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol","volume":"15","author":"Micallef","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"10.1016\/j.transci.2025.104304_bib12","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41409-024-02385-1","article-title":"Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma","volume":"59","author":"Avigan","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.transci.2025.104304_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2025.104304_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s12288-017-0798-8","article-title":"Single-dose preemptive plerixafor for stem cell mobilization for ASCT after lenalidomide-based therapy in multiple myeloma: impact in a resource-limited setting","volume":"33","author":"Kumar","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"10.1016\/j.transci.2025.104304_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","article-title":"Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34\u207a cell levels and preemptive intervention vs remobilization","volume":"50","author":"S\u00e1nchez-Ortega","year":"2015","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2025.104304_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225002472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225002472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:04:05Z","timestamp":1769760245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225002472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1473050225002472"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104304","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104304"}}